XNAS
NTRB
Market cap82mUSD
Oct 08, Last price
6.05USD
1D
-10.44%
1Q
104.39%
IPO
33.60%
Name
Nutriband Inc
Chart & performance
P/E
—
P/S
36.11
EPS
—
Div yield, %
—
Shrs. gr., 5y
11.57%
Rev. gr., 5y
16.63%
Revenues
2m
-4.83%
Net income
-8m
L-21.50%
CFO
-5m
L+10.97%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nutriband Inc. is a pharmaceutical company dedicated to advancing a diverse pipeline of transdermal drug products. Foremost among its developmental initiatives is an abuse-deterrent fentanyl transdermal system. This innovative patch aims to provide both healthcare providers and patients with an extended-release fentanyl solution for the effective management of chronic pain. Beyond its core transdermal portfolio, Nutriband Inc. also holds a licensing agreement with Rambam Med-Tech Ltd. for the development of RAMBAM Closed System Transfer Devices. Established in 2016, the company maintains its corporate headquarters in Orlando, Florida.
Key people
Sean Gallagher
Company President and Director · since 2018
Gareth Sheridan
Chief Executive Officer, Director · since 2016
Serguei Melnik
Chief Financial Officer, Director · since 2016
Alan Smith
Chief Operating Officer, President - 4P Therapeutics · since 2018
Patrick Ryan
Chief Technical Officer · since 2018
Jeff Patrick
Chief Scientific Officer · since 2018
Radu Bujoreanu
Independent Director · since 2019
Independent Director · since 2018
Michael Doron
Independent Director · since 2018
Mark Hamilton
Independent Director · since 2018
Woody Jay Moore
Independent Director · since 2018
Legal address
C/O Incorp Services, Inc.
3773 Howard Hughes Parkway
Suite 500S
Las Vegas, NV 89169
US
3773 Howard Hughes Parkway
Suite 500S
Las Vegas, NV 89169
US
Headquarters
309 Celtic Court
Oviedo, FL 32765
US
Oviedo, FL 32765
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑01 | 2025‑01 | 2024‑01 | 2023‑01 | 2022‑01 | 2021‑01 | 2020‑01 | 2019‑01 | 2018‑01 | 2017‑01 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||